1 The primary outcome

was the proportion of children developing histologically prov

2 The primary outcome

was the proportion of clinical failures (development of sever

3 nce and lower leg longitudinal growth were also similar, as

was the proportion of cumulative total enteral feeding volume

4 The primary outcome

was the proportion of duodenoscopes with an elevator mechanis

5 The primary outcome

was the proportion of households in which at least one child

6 The primary outcome

was the proportion of individuals testing with a partner.

7 The primary outcome

was the proportion of individuals who had one or more osteopo

8 The primary endpoint

was the proportion of participants achieving sustained virolo

9 The primary endpoint

was the proportion of participants achieving sustained virolo

10 The primary outcome

was the proportion of participants in whom a diagnosis of cur

11 The primary outcome

was the proportion of participants with culture-positive pulm

12 The primary endpoint

was the proportion of participants with HIV-1 RNA less than 4

13 The primary endpoint

was the proportion of participants with less than 50 copies p

14 The primary outcome

was the proportion of participants with plasma HIV-1 RNA conc

15 The primary endpoint

was the proportion of participants with plasma HIV-1 RNA of l

16 The primary endpoint

was the proportion of participants with plasma HIV-1 RNA of l

17 The non-inferiority primary effectiveness outcome

was the proportion of participants with three or fewer bliste

18 The primary endpoint

was the proportion of participants with undetectable HIV-RNA

19 The primary outcome

was the proportion of participants with virological rebound (

20 The primary efficacy measure

was the proportion of patients achieving a >/=50% reduction i

21 The primary endpoint

was the proportion of patients achieving an objective (comple

22 The primary efficacy end point

was the proportion of patients achieving greater than 30% red

23 The primary endpoint

was the proportion of patients achieving haematocrit control

24 A secondary efficacy end point

was the proportion of patients achieving mean PTH of 300 pg/m

25 The primary endpoint

was the proportion of patients considered responders at 24 h.

26 The primary end point

was the proportion of patients having at least 1 skeletal-rel

27 The primary endpoint

was the proportion of patients in each group with an mUFC con

28 The primary endpoint

was the proportion of patients in the intention-to-treat popu

29 The primary outcome

was the proportion of patients receiving the preferred beta-l

30 The primary efficacy outcome

was the proportion of patients remaining free from seizures f

31 Primary outcome

was the proportion of patients returning to preoperative func

32 The primary end point

was the proportion of patients who achieved a >/=1.0 g/dl inc

33 The primary endpoint for this study

was the proportion of patients who achieved an overall respon

34 The primary endpoint

was the proportion of patients who attained an American Colle

35 The primary efficacy end point

was the proportion of patients who developed AKI according to

36 The primary outcome

was the proportion of patients who received antibiotics while

37 The primary end point

was the proportion of patients with 1 or more SRE on study (S

38 The primary outcome

was the proportion of patients with a CIDP relapse or who wer

39 The primary endpoint of the initial study

was the proportion of patients with a haematological response

40 Primary outcome measure

was the proportion of patients with a stable retinal reattach

41 The primary outcome

was the proportion of patients with an adequate clinical and

42 The primary end point

was the proportion of patients with complete clinical respons

43 The primary outcome

was the proportion of patients with microbiologically documen

44 The primary outcome

was the proportion of patients with successful first-pass int

45 The primary outcome

was the proportion of patients with successful revascularizat

46 The primary efficacy endpoint

was the proportion of patients with SVR at 12 weeks after tre

47 Exposure

was the proportion of pregnancy protected by IRS.

48 The primary end point

was the proportion of subjects developing at least 1 small-bo

49 The primary outcome

was the proportion of success at 12 months, defined as improv

50 The primary outcome

was the proportion of time when sensor glucose concentration